• PDF / 169,987 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 15 Downloads / 179 Views

DOWNLOAD

REPORT

---

1

S

Nontuberculous mycobacterial lung disease: 3 case reports In a retrospective analysis of 15 chronic obstructive pulmonary disease (COPD) patients, 3 patients [ages and sexes not stated] were described, who developed non-tuberculous mycobacterial lung disease during treatment with budesonide or fluticasone propionate. The patients were receiving inhalation of fluticasone propionate 500µg twice a day (one patient) or budesonide 160µg twice a day (two patients) for COPD. Subsequently, the patients developed non-tuberculous mycobacterial lung disease [times to reaction onsets not stated]. Consequently, the patient receiving fluticasone propionate was switched to budesonide. Of the remaining two patients, budesonide treatment was maintained in one patient, while budesonide dose was reduced in the other patient [outcomes not stated]. Author comment: Three patients continued their [budesonide or fluticasone propionate] treatment after the confirmed diagnosis of NTM-LD. One case changed from 500 µg of fluticasone, 2 times/d, to 160 µg budesonide, 2 times/ d; one maintained 160 µg of budesonide, 2 times/d; 160 µg of budesonide, 2 times/d, to 80 µg of budesonide, 2 times/d. Sun YX, et al. [The clinical analysis of chronic obstructive pulmonary disease patients complicated with nontuberculous mycobacterial pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi 42: 826-831, No. 11, Nov 2019. Available from: URL: http://doi.org/10.3760/cma.j.issn.1001-0939.2019.11.008 [Chinese; 803441137 summarised from a translation] - China

0114-9954/19/1784-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 21 Dec 2019 No. 1784